Clinical Trial

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase I/II trial studies the best dose, possible benefits and/or side effects of oral azacitidine in treating patients with T-cell large granular lymphocytic leukemia that has come back (relapsed) or has not responded to previous treatment (refractory). Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Protocol Amendment History 2 changes
minor Completion pushed: 2026-06-30 -> 2026-09-30 2026-07-29
notable Primary completion moved earlier: 2026-06-15 -> 2026-02-19 2026-07-10
Trial Details
NCT Number NCT05141682
Lead Sponsor Jonathan Brammer
Collaborators: Bristol-Myers Squibb
Conditions T-Cell Large Granular Lymphocyte Leukemia
Enrollment 11 participants
Start Date 2022-06-29
Primary Completion 2026-02-19 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-28